Last update April 21, 2021
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Lisdexamfetamine Mesilate is also known as
Lisdexamfetamine Mesilate in other languages or writings:
|Protein Binding||16 - 20||%|
|VD||3.2 - 5.6||l/Kg|
|Tmax||3.5 - 4.7||hours|
|T½||6.8 - 12||hours|
|M/P ratio||3.3 (2.2 - 4.8)||-|
|Theoretical Dose||5.7 (4 - 10.6)||mg/Kg/d|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
A prodrug that is metabolized directly in the intestine to dextroamphetamine. It is used to treat Attention Deficit Hyperactivity Disorder (ADHD) and bulimia.
Dextroamfetamine is a sympathomimetic drug, central nervous system stimulant, whose action and uses are similar to amphetamine (see information) which is its dextro isomer.
It is excreted in breast milk, concentrating about 3 times more than in plasma and resulting in a relative dose of around 6% for the infant (Ilett, 2007).
In infants whose mothers were taking dexamfetamine as treatment for ADHD, levels ranging from undetectable to 14% of maternal plasma levels have been measured and no problems were observed in the clinical follow-up of these infants (Ilett, 2007).
There is little information on the impact of amphetamine abuse on infant development and health (Oei, 2012, Wise, 2007; Moretti, 2000), but it is known that they are more exposed to social problems, domestic violence, and lower rates of breastfeeding (Oei, 2010).
There is controversy over the possibly mild negative effect of amphetamine on prolactin (Petraglia, 1987; DeLeo, 1983), but milk production in mothers who took it therapeutically was not affected (Öhman, 2015).
During breastfeeding, the therapeutic use (ADHD, bulimia) of amphetamine can be assessed, using the lowest possible effective dose and monitoring the occurrence of irritability, insomnia, lack of appetite and weight loss.
Its use as an illegal drug is totally discouraged (Oei, 2012).
To minimize the risk, after the last recreational use of amphetamine, it is advisable to wait 60 hours (5 T ½, which eliminates 97% of the substance) before breastfeeding again. Meanwhile, express and discard milk from the breast regularly to maintain production.
See below the information of this related product: